NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for CML recommend ongoing monitoring to detect disease progression and loss of response¹

For patients who fail to meet these milestones, the National Comprehensive Cancer Network^® (NCCN^®) recommends:¹

• Evaluation of patient compliance and drug interactions
• Mutational analysis
• Consideration of subsequent treatment options^b

^aAchievement of response milestones must be interpreted within the clinical context. Patients with >50% reduction compared to baseline or minimally above the 10% cutoff can continue the same dose of dasatinib or nilotinib for another 3 months.

^bOptions depend on level of response and include continuing on same TKI or switching TKIs; if currently on imatinib, escalating dose up to a maximum of 800 mg; or evaluating for hematopoietic transplantation. See the NCCN Guidelines^® for specific recommendations.

REFERENCE

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Chronic Myeloid Leukemia, Version 1.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed July 26, 2017. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way.